Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma | Science Translational Medicine
A genetic mouse model of IDH-mutant glioma responds to mutant IDH inhibitor (mIDHi) and shows that prior mIDHi treatment improves response to chemoradiation.
